Aurobindo Pharma subsidiary completes acquisition of A1 Biochem Group business

Aurobindo Pharma Ltd announced the completion of the acquisition of the Contract Research Services business of A1 Biochem Group by its wholly owned subsidiary, Apitoria Pharma Private Limited. This acquisition involves Apitoria holding 80% ownership in A1 Biochem Labs (India) Private Limited ('A1 Labs India'), with the remaining 20% held by Dr. Rajendra Gadikota. A1 Labs India, through its US subsidiary, has acquired 100% of A1 Biochem Labs LLC, USA. This strategic move provides Apitoria with access to an established CRO platform with over 50 clients and extensive project experience in India and the USA. The acquisition is expected to complement Apitoria's manufacturing capabilities, creating an integrated CRDMO platform and broadening its service offerings and customer engagement.